|Founded||Hayward, California, United States (1995)|
|Headquarters||Hayward, California, United States|
|Products||(none as of 2012)|
Intarcia Therapeutics is an American pharmaceutical company based in Hayward, California and incorporated under the laws of Delaware. It was founded in 1995 under the name "BioMedicines" and changed to its present name in 2004. In April 2012, the company announced its intention to relocate its headquarters to the Boston-area.
In 2005, the executive leadership of Intarcia was largely vested in two people, Karling Leung and James Ahlers, President/CEO/Director and Vice President/CFO/Finance & Operations Officer, respectively. By 2012, Kurt Graves had replaced Karling Leung as President and CEO.
As of 2012[update], Intarcia is engaged in development of a "potential once-a-year type 2 diabetes treatment". Referred to as ITCA-650, the therapeutic consists of exenatide delivered via its DUROS system, "a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides".
In November 2012, Intarcia received $210M in preferred stock and debt financing from, The Baupost Group, Farallon Capital Management, New Enterprise Associates, New Leaf Venture Partners and Venrock Associates.  Other Investors include Greenspring Associates , Alta Partners and Granite Venture Partners.
- "Company Overview of Intarcia Therapeutics, Inc.", Bloomberg Businessweek, retrieved November 15, 2012
- Exhibit 4.1, SEC, retrieved November 15, 2012
- Radius Health, Inc. (FORM S-1), SEC, February 6, 2012, retrieved November 15, 2012
- "INTARCIA THERAPEUTICS, INC.", AMENDMENT NO. 1 TO FORM S-1 (SEC), March 18, 2005, retrieved November 15, 2012
- Ron Leuty (November 15, 2012), "Intarcia raises $210M as it pushes once-a-year diabetes treatment into Phase III, moves HQ to Boston area", San Francisco Business Times, retrieved November 15, 2012
- Don Seiffert (November 15, 2012), "Intarcia, in midst of move to Boston, raises $210M", Mass High Tech (American City Business Journals), retrieved November 15, 2012
- "Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus", ClinicalTrials.gov, May 1, 2012, retrieved November 15, 2012
- "AtTaIntarcia raises $210M as it pushes once-a-year diabetes treatment into Phase III, moves HQ to Boston area". BizJournals. November 15, 2012. Retrieved November 7, 2013.
- "Direct Investments". Greenspring Associates. 2013-11-07. Retrieved 2013-11-07.
|This United States corporation or company article is a stub. You can help Wikipedia by expanding it.|